Since the incorporation of AtriCure® in November 2000, AtriCure’s commitment to innovation has been relentless.
August 2001:
FDA grants 510(k) clearance to market the bipolar ablation system for the ablation of soft tissues.
July 2002:
Bipolar ablation system released to the market. Received CE Mark approval to market the system throughout the European Union and certifications in several other foreign markets.
September 2002:
Received the coveted Emerging Technology Award from the Ohio Department of Development (ODOD) through the Office of Governor.
July 2004:
FDA grants 510(k) clearance to market the Lumitip™ dissector for the dissection of soft tissues.
February 2005:
Received CE Mark approval for the Lumitip™ dissector to market throughout the European Union.
June 2005:
FDA grants 510(k) clearance to market the Isolator® pen for the ablation of cardiac tissue during cardiac surgery.
July 2005:
Received CE Mark approval for the Isolator pen to market throughout the European Union, and certifications in other foreign markets.
August 2005:
AtriCure issued 4,150,000 shares of common stock, with gross proceeds of $49.8 million, in their initial public offering.
AtriCure acquires Enable Medical Corporation for $7 million. Enable manufactures AtriCure's Isolator handpieces, an essential component of AtriCure's bipolar ablation system.
October 2005:
FDA grants 510(k) clearance to market Isolator® endoscopic ablation clamps with the Glidepath™ transfer guide for the ablation of soft tissues.
July 2006:
FDA grants 510(k) clearance to market the Isolator multifunctional pen for temporary cardiac pacing, sensing, and stimulation during the evaluation of cardiac arrhythmias during surgery.
September 2006:
Received CE Mark approval to market the bipolar ablation system for ablation of cardiac tissue and the treatment of atrial fibrillation throughout the European Union.
January 2007:
FDA grants 510(k) clearance to market the Isolator® Synergy™ system for the ablation of soft tissues.
June 2007:
AtriCure's Quality and Regulatory Departments were recognized in Medical Device & Diagnostic Industry for "Outstanding Quality and Regulatory Teams". AtriCure was 1 of 8 companies recognized.
July 2007:
FDA grants 510(k) clearance to market the Isolator® bipolar (transpolar) ablation clamp system for the ablation of cardiac tissue.
Join the Team!
AtriCure is always interested in finding dedicated individuals to join the fast-paced team to fill challenging positions both in Cincinnati, Ohio, and in the field. If you have a desire to make a difference in the work of surgeons and the lives of patients, we want to hear from you.